Evofem Biosciences, Inc.
EVFM
$0.01
$0.002.67%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.49% | 21.87% | 4.23% | 3.67% | -2.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.49% | 21.87% | 4.23% | 3.67% | -2.51% |
| Cost of Revenue | 26.19% | 32.63% | 20.42% | 7.97% | -18.51% |
| Gross Profit | -1.03% | 18.98% | 0.24% | 2.66% | 2.62% |
| SG&A Expenses | -21.88% | -19.29% | -17.67% | -6.92% | -5.65% |
| Depreciation & Amortization | -72.81% | -58.31% | -19.39% | 141.86% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.10% | 12.24% | -30.68% | -24.00% | -25.08% |
| Operating Income | -7.51% | 23.26% | 118.75% | 71.06% | 60.89% |
| Income Before Tax | -145.35% | -94.80% | 104.44% | 31.57% | -110.31% |
| Income Tax Expenses | -500.00% | -- | -- | -- | -105.26% |
| Earnings from Continuing Operations | -145.30% | -94.83% | 104.41% | 31.54% | -110.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -145.30% | -94.83% | 104.41% | 31.54% | -110.31% |
| EBIT | -7.51% | 23.26% | 118.75% | 71.06% | 60.89% |
| EBITDA | -30.11% | 15.11% | 127.85% | 77.72% | 69.36% |
| EPS Basic | -95.01% | -97.29% | 99.16% | 91.72% | -100.40% |
| Normalized Basic EPS | -98.35% | -184.14% | 92.41% | 82.76% | 97.72% |
| EPS Diluted | -100.15% | -33.21% | 86.64% | 93.70% | 91.39% |
| Normalized Diluted EPS | -102.90% | -67.19% | 81.87% | 81.59% | 82.72% |
| Average Basic Shares Outstanding | 21.59% | 34.11% | 67.94% | 125.16% | 287.22% |
| Average Diluted Shares Outstanding | 297.18% | 222.56% | 1,617.96% | 270.84% | 171.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |